trending Market Intelligence /marketintelligence/en/news-insights/trending/wl7x-jnAHMKaTElEn7RlGA2 content esgSubNav
In This List

Mylan receives tentative US approval for generic HIV treatment

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Mylan receives tentative US approval for generic HIV treatment

The U.S Food and Drug Administration granted tentative approval to Mylan NV's generic HIV treatment under the U.S. President's Emergency Plan for AIDS Relief.

The anti-retroviral treatment, known as TDF-3TC-DTG, or TLD, is recommended as the first line of treatment for patients in developing countries. The drug combines the active ingredients from three brand-name medicines: ViiV Healthcare's Tivicay and Epivir, and Gilead Sciences Inc.'s Viread.

The U.S. President's Emergency Plan for AIDS Relief is a U.S. government initiative to address the global HIV/AIDS epidemic, primarily in Africa.

ViiV Healthcare is majority owned by GlaxoSmithKline plc